Modifying factors of the HFE hemochromatosis phenotype

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 4, 2008, Pages 531-540

  Deugnier, Yves ^a   Mosser, Jean ^b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Hemochromatosis; Hepcidin; HFE; Modifier factor; Penetrance

Indexed keywords

HEPCIDIN; HFE PROTEIN; NIFEDIPINE; PROTON PUMP INHIBITOR; SMAD PROTEIN; TRANSFERRIN;

ALCOHOL CONSUMPTION; ARTHRITIS; ARTICLE; BLOOD DONOR; CHRONIC DISEASE; DIETARY INTAKE; ENVIRONMENTAL FACTOR; FATIGUE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEMOCHROMATOSIS; HEREDITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFLAMMATION; IRON ABSORPTION; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; LIFE EXPECTANCY; LIVER DISEASE; METABOLIC SYNDROME X; NONHUMAN; PENETRANCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; SEX DIFFERENCE; SIGNAL TRANSDUCTION;

EID: 55749102251     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.4.531     Document Type: Article

References (90)

1. Finch C. Iron metabolism in hemochromatosis. J. Clin. Invest. 28, 780 (1949).
2. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N. Engl. J. Med. 313(20), 1256-1262 (1985).
3. Simon M, Bourel M, Fauchet R, Genetet B. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut 17(5), 332-334 (1976).
4. Simon M, Bourel M, Genetet B, Fauchet R. Idiopathic hemochromatosis. Demonstration of recessive transmission and early detection by family HLA typing. N. Engl. J. Med. 297(19), 1017-1021 (1977).
5. Feder JN, Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 13(4), 399-408 (1996).
6. Pietrangelo A, Non-HFE hemochromatosis. Hepatology 39(1), 21-29 (2004).
7. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet. Test. 4(2), 183-198 (2000).
8. Brissot P, Moirand R, Jouanolle AM et al. A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria. J. Hepatol. 30(4), 588-593 (1999).
9. Anderson GJ, Darshan D, Wilkins SJ, Frazer DM. Regulation of systemic iron homeostasis: how the body responds to changes in iron demand. Biometals 20(3-4), 665-674 (2007).
10. Ganz T. Molecular control of iron transport. J. Am. Soc. Nephrol. 18 (2), 394-400 (2007).
11. Ganz T. Iron homeostasis: fitting the puzzle pieces together. Cell Metab. 7(4), 288-290 (2008).
12. Pigeon C, Ilyin G, Courseland B et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem. 276(11), 7811-7819 (2001).
13. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101(7), 2461-2463 (2003).
14. Nicolas G, Bennoun M, Devaux I et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc. Natl Acad. Sci. USA 98(15), 8780-8785 (2001).
15. De Domenico I, Ward DM, Langelier C et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol. Biol. Cell 18(7), 2569-2578 (2007).
16. Nemeth E, Turtle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306(5704), 2090-2093 (2004).
17. Bekri S, Gual P, Anty R et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 131(3), 788-796 (2006).
18. Peyssonnaux C, Zinkernagel AS, Datta V, Lauth X, Johnson RS, Nizet V. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 107(9), 3727-3732 (2006).
19. Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 110(7), 1037-1044 (2002).
20. Babitt JL, Huang FW, Wrighting DM et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat. Genet. 38 (5), 531-539 (2006).
21. Truksa J, Peng H, Lee P, Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin I expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc. Natl Acad. Sci. USA 103(27), 10289-10293 (2006).
22. Wang RH, Li C, Xu X et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2(6), 399-409 (2005).
23. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J. Clin. Invest. 117(7), 1933-1939 (2007).
24. Lin L, Valore EV, Nemeth E, Goodnough JB, Gabayan V, Ganz T. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood 110(6), 2182-2189 (2007).
25. Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC. The transferrin receptor modulates HFE-dependent regulation of hepcidin expression. Cell Metab. 7(3), 205-214 (2008).
26. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374(Pt 1), 1-20 (2003).
27. Pietrangelo A, Dierssen U, Valli L et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 132(1), 294-300 (2007).
28. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stoke J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109(1), 353-358 (2007).
29. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 108(9), 3204-3209 (2006).
30. Fukuda S, Abematsu M, Moti H et al. Potentiation of astrogliogenesis by STAT3-mediated activation of bone morphogenetic protein-SMAD signaling in neural stem cells. Mol. Cell. Biol. 27(13), 4931-4937 (2007).
31. Tanno T, Bhanu NV, Oneal PA et al. High levels of GDF 15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med. 13 (9), 1096-1101 (2007).
32. Courselaud B, Pigeon C, Inoue Y et al. C/EBPa regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J. Biol. Chem. 277(43), 41163-41170 (2002).
33. Pinto JP, Ribeiro S, Pontes H et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signalling and regulation of C/EBPa. Blood (2008) (In press).
34. Harrison-Findik DD. Role of alcohol in the regulation of iron metabolism. World J. Gastroenterol. 13(37), 4925-4930 (2007).
35. Brissot P, de Bels F. Current approaches to the management of hemochromatosis. Hematology 36-41 (2006).
36. Deugnier Y, Turlin B, le Quilleuc D et al. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis. Am. J. Surg. Pathol. 21(6), 669-675 (1997).
37. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 112(3), 882-888 (1997).
38. Asberg A, Hveem K, Thorstensen K et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand. J. Gastroenterol. 36(10), 1108-1115 (2001).
39. Adams PC, Reboussin DM, Barton JC et al. Hemochromatosis and iron-overload screening in a racially diverse population. N. Engl. J. Med. 352(17), 1769-1778 (2005).
40. Allen KJ, Gurrin LC, Constantine CC et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 358(3), 221-230 (2008).
41. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 103(8), 2914-2919 (2004).
42. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845GA (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359(9302), 211-218 (2002).
43. Deugnier Y, Mosser J. The genotype-phenotype interaction in HFE hemochromatosis. Expert Rev. Gastroenterol. Hepatol. (2008) (In Press).
44. Jackson HA, Carter K, Darke C et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br. J. Haematol. 114(2), 474-484 (2001).
45. Deugnier Y, Jouanolle AM, Chaperon J et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people. Br. J. Haematol. 118(4), 1170-1178 (2002).
46. Guyader D, Jacquefinet C, Moirand R et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 115(4), 929-936 (1998).
47. Piippo K, Louhija J, Tilvis R, Kontula K. You may live to the age of more than 100 years even if you are homozygous for a haemochromatosis gene mutation. Eur. J. Clin. Invest. 33(9), 830-831 (2003).
48. Coppin H, Bensaid M, Fruchon S, Borot N, Blanche H, Roth MP. Longevity and carrying the C282Y mutation for haemochromatosis on the FIFE gene: case control study of 492 French centenarians. Br. Med. J. 327(7407), 132-133 (2003).
49. Van Aken MO, De Craen AJ, Gussekloo J et al. No increase in mortality and morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old: the Leiden 85-plus study. Eur. J. Clin. Invest. 32(10), 750-754 (2002).
50. Waalen J, Nordestgaard BG, Beutler E. The penetrance of hereditary hemochromatosis. Best Pract. Res. Clin. Haematol. 18(2), 203-220 (2005).
51. Burt MJ, George PM, Upton JD et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut 43 (6), 830-836 (1998).
52. Merryweather-Clarke AT, Worwood M, Parkinson L et al. The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. Br. J. Haematol. 101(2), 369-373 (1998).
53. Njajou OT, Houwing-Duistermaat JJ, Osborne RH et al. A population-based study of the effect of the HFE C282Y and H63D mutations on iron metabolism. Eur. J. Hum. Genet. 11(3), 225-231 (2003).
54. Crawford DH, Jazwinska EC, Cullen LM, Powell LW. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 114(5), 1003-1008 (1998).
55. Walsh A, Dixon JL, Ramm GA et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin. Gastroenterol. Hepatol. 4(11), 1403-1410 (2006).
56. Moirand R, Jouanolle AM, Brissot P, Le Gall JY, David V, Deugnier Y. Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives. Gastroenterology 116(2), 372-377 (1999).
57. Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann. Intern. Med. 133(5), 329-337 (2000).
58. Mura C, Raguenes O, Ferec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 93(8), 2502-2505 (1999).
59. Piperno A, Arosio C, Fossati L et al. Two novel nonsense mutations of HFE gene in five unrelated italian patients with hemochromatosis. Gastroenterology 119(2), 441-445 (2000).
60. Wallace DF, Dooley JS, Walker AP. A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Gastroenterology 116(6), 1409-1412 (1999).
61. Steiner M, Ocran K, Genschel J et al. A homozygous HFE gene splice site mutation (IVS5+1 G/A) in a hereditary hemochromatosis patient of Vietnamese origin. Gastroenterology 122 (3), 789-795 (2002).
62. van der AD, Peeters PH, Grobbee DE, Roest M, Voorbij HA, van der Schouw Yr. HFE genotypes and dietary heme iron: no evidence of strong gene-nutrient interaction on serum ferritin concentrations in middle-aged women. Nutr. Metab. Cardiovasc. Dis. 16(1), 60-68 (2006).
63. Cade JE, Moreton JA, O'Hara B et al. Diet and genetic factors associated with iron status in middle-aged women. Am. J. Clin. Nutr. 82(4), 813-820 (2005).
64. Kakwasser JP, Werner E, Schalk K, Hansen C, Gottschalk R, Seidl C. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 43(5), 699-704 (1998).
65. Bridle K, Cheung TK, Murphy T et al. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin. Exp. Res. 30(1), 106-112 (2006).
66. Detivaud L, Nemeth E, Boudjema K et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 106(2), 746-748 (2005).
67. Barton JC, Preston BL, McDonnell SM, Rothenberg BE. Severity of iron overload in hemochromatosis: effect of volunteer blood donation before diagnosis. Transfusion 41(1), 123-129 (2001).
68. Laine F, Jouannolle AM, Morcet J et al. Phenotypic expression in detected C282Y homozygous women depends on body mass index. J. Hepatol. 43(6), 1055-1059 (2005).
69. Laine F, Deugnier Y. Increased expression of hepcidin in obese patients: impact on phenotypic expression of hemochromatosis and pathophysiology of dysmetabolic iron overload syndrome. Gastroenterology 131 (6), 2028 (2006).
70. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N. Engl. J. Med. 341(10), 718-724 (1999).
71. Distante S, Berg JP, Lande K, Haug E, Bell H. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis. Gut 47(4), 575-579 (2000).
72. Beutler E, Waalen J, Gelbart T. Chronic inflammation does not appear to modify the homozygous hereditary hemochromatosis phenotype. Blood Cells Mol. Dis. 35(3), 326-327, (2005).
73. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 56(9), 1291-1295 (2007).
74. 2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nat. Med. 13(4), 448-454 (2007).
75. Moirand R, Adams PC, Bicheler V, Brissot P, Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men. Ann. Intern. Med. 127(2), 105-110 (1997).
76. Bulaj ZJ, Ajioka RS, Phillips JD et al. Disease-related conditions in relatives of patients with hemochromatosis. N. Engl. J. Med. 343(21), 1529-1535 (2000).
77. Whiting PW, Fletcher LM, Dixon JK, Gochee P, Powell LW, Crawford DH. Concordance of iron indices in homozygote and heterozygote sibling pairs in hemochromatosis families: implications for family screening. J. Hepatol. 37(3), 309-314 (2002).
78. Whitfield JB, Cullen LM, Jazwinska EC et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am. J. Hum. Genet. 66(4), 1246-1258 (2000).
79. Bensaid M, Fruchon S, Mazeres C, Bahrain S, Roth MP, Coppin H. Multigenic control of hepatic iron loading in a murine model of hemochromatosis. Gastroenterology 126(5), 1400-1408 (2004).
80. Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 103 (7), 2835-2840 (2004).
81. Merryweather-Clarke AT, Cadet E, Bomford A et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum. Mol. Genet. 12(17), 2241-2247 (2003).
82. Le Gac G, Scotet V, Ka C et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum. Mol. Genet. 13(17), 1913-1918 (2004).
83. Milet J, Dehais V, Bourgain C et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance. Am. J. Hum. Genet. 81(4), 799-807 (2007).
84. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 122(2), 281-289 (2002).
85. Loreal O, Deugnier Y, Moirand R et al. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J. Hepatol. 16(1-2), 122-127 (1992).
86. Powell EE, Ali A, Clouston AD et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 129(6), 1937-1943 (2005).
87. Livesey KJ, Wimhurst VL, Carter K et al. The 16189 variant of mitochondrial DNA occurs more frequently in C282Y homozygotes with haemochromatosis than those without iron loading, J. Med. Genet. 41(1), 6-10 (2004).
88. Beutler E, Beutler L, Lee PL, Barton JC. The mitochondrial nt 16189 polymorphism and hereditary hemochromatosis. Blood Cells Mol. Dis. 33(3), 344-345 (2004).
89. Osterreicher CH, Datz C, Stickel F et al. TGF-β1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine 31(2), 142-148 (2005).
90. Valenti L, Conte D, Piperno A et al. The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. J. Med. Genet. 41(12), 946-950 (2004).